Tag: Pause

Categories
Health

Novavax Says U.S. Will Pause Funding for Manufacturing of Its Vaccine

Novavax Says U.S. Will Pause Funding for Production of Its Vaccine

WASHINGTON – Novavax, the Maryland company that won a federal $ 1.75 billion contract to develop and manufacture a coronavirus vaccine, said Thursday that the federal government will not fund further production of its vaccine until the company does has dispelled the concerns of the federal supervisory authorities about its work.

The company’s disclosure was made in a quarterly filing with the Securities and Exchange Commission. The Trump administration agreed to purchase 110 million doses of vaccine from Novavax as part of its crash vaccine development program.

Although the company reported in June that its vaccine was 90 percent effective against symptomatic Covid-19 cases and 100 percent against serious illnesses, Novavax has been battling mass production of its product for months. His vaccine has not been approved for sale in the United States, and federal officials said it was unclear when or if it would.

Four people familiar with Novavax operations said the company has not yet been able to demonstrate that its production process complies with Food and Drug Administration standards. They spoke on condition of anonymity to discuss sensitive contractual issues.

In its SEC filing on Thursday, Novavax said, “The US government recently directed the company to prioritize coordination with the US Food and Drug Administration on the company’s analytical methods before engaging in additional US productions. and has further advised that the US government will not allocate additional funding to US production until such an agreement is reached. “

An official with the Department of Health and Human Services overseeing Novavax’s federal contract said the government wanted the company to step up its testing and quality controls. The officer spoke on condition of anonymity to discuss confidential negotiations with the company.

Novavax said in a statement that the federal government is continuing to fund other ongoing work, including clinical trials. “We do not anticipate any impact on our funding agreement with the US government to support the overall development and production of 110 million doses of our vaccine candidate,” the company said.

The company’s manufacturing problems are on top of lost production at a government-funded vaccine-making factory in Baltimore operated by Emergent BioSolutions.

Federal regulators suspended production at that facility for more than three months this year until the company resolved quality control issues, including a failure to prevent contamination that ruined tens of millions of cans. The plant had made Johnson & Johnson and AstraZeneca vaccines but now only makes doses for Johnson & Johnson.

Chris Hamby contributed to the coverage.

Categories
Business

Confidence within the security of the J&J vaccine is low following U.S. pause, Kaiser survey reveals

Confidence in the safety of the J&J vaccine is low following U.S. pause, Kaiser survey shows

An Army nurse holds a vial of the Johnson & Johnson vaccine at the FEMA-sponsored COVID-19 vaccination site at Valencia State College on the first day the site provided the Johnson & Johnson vaccine after the FDA repealed The CDC has offered a break again due to blood clot concerns.

Paul Hennessy | LightRocket | Getty Images

According to a new survey by the Kaiser Family Foundation, less than half of Americans believe the Johnson & Johnson Covid-19 vaccine is safe after it was temporarily suspended in the US after reports of rare blood clotting problems in some recipients.

While most people believe in Covid vaccines, in general, only 46% of respondents said they were at least somewhat confident about the J&J inclusion, compared to 69% who were for both Pfizer and the Moderna vaccines said. Kaiser surveyed 2,097 randomly selected adults aged 18 and over from April 15 to 29 for the study published on Wednesday.

The Food and Drug Administration and Centers for Disease Control and Prevention urged states on April 13 to temporarily stop using J & J’s vaccine “out of caution” after six women reported rare blood clots. A CDC panel recommended the US resume the vaccine ten days later, saying the benefits outweigh the risks.

The J&J news seems to have changed some opinions about a shot.

One in five non-vaccinated respondents said the news changed their minds about receiving the vaccine, even though the specific responses were different. 7% said they were less likely to want any of the three Covid vaccines, Kaiser noted. Another 9% said they were less likely to want the J&J vaccine, but that it didn’t change their mind about the Pfizer or Moderna shots.

Nevertheless, the proportion of respondents who said they had received a shot rose significantly from 32% to 56% in the survey last month. That number reflects data from the CDC, which reports that roughly the same proportion of adults in the United States have received one or more doses.

“The news was widespread and it certainly hurt confidence in J&J, but it’s not clear that it had much of an impact on whether or not people were actually vaccinated,” said Dr. Mollyann Brodie, General Manager of Public Opinion and Survey Research at the Foundation Program. “It confirmed for people who were concerned about side effects that there were side effects, but we know that the immediate effect – at least in terms of what people told us – is very small in terms of demand.”

Women were more likely than men to say the J&J news had changed their minds about vaccination. The Kaiser survey found that Hispanic women in particular, 18% of whom said they were less likely to want a vaccine at all.

The timing of the Johnson & Johnson hiatus coincides with a general slowdown in US vaccinations. The country reported an average of 2.1 million vaccinations per day for the past week, CDC data shows, up from a high of 3.4 million on April 13.

The fact that the nationwide drop in daily shots occurred during the stop is more a coincidence than a direct effect, said Dr. Rupali Limaye, faculty member at the Johns Hopkins Bloomberg School of Public Health. Limaye is researching vaccine decision-making and has worked with state health departments during the vaccine launch.

While the hiatus at J&J, and the reluctance it caused, contributed somewhat to the decline, the bigger factor, according to Limaye, is that the country has reached the point where most Americans who want a vaccine have got one.

“I hear from states that not only are things slowing down generally because of J&J, but also slowing down because we have essentially been able to meet the demand,” she said.

The survey data from the Kaiser Foundation confirm this. Respondents who said they were most anxious to get a shot – those who have already been vaccinated or want it as soon as possible – rose only marginally from 61% to 64% in the previous survey in March. The proportion who wanted to “wait and see” before vaccination, who had lost in size, remained roughly the same.

“We are at a stage in the vaccination effort where all the eager people are vaccinated or are about to be vaccinated,” said Brodie. “We are now turning to the reluctant people, with strategies that are required to reach many different people.”

This equates to an 87% decline, which is steeper than the declines Pfizer and Moderna saw from their respective peaks.

Categories
Health

Physician on CDC advisory panel expects pause lifted

Doctor on CDC advisory panel expects pause lifted

A member of a key CDC advisory body told CNBC Friday morning that he expects the U.S. hiatus on Johnson & Johnson’s one-off coronavirus vaccine to be lifted at some point.

“I think we are ready to use this vaccine. We had to take an important pause to review this safety information to consider the risks. But I think there is a large amount of evidence that the Benefit far outweighs this risk, “said Dr. Wilbur Chen, professor in the University of Maryland School of Medicine.

Chen spoke on the Worldwide Exchange before attending a meeting of the Agency’s Advisory Committee on Immunization Practices later on Friday to discuss the rare but serious bleeding disorder some women had after receiving the J&J shot.

In addition to the six patients who experienced rare but severe blood clotting problems after receiving the vaccine, the CDC is investigating two other possible cases: a deceased Oregon woman and a Texas woman who was hospitalized. Of the original six women, one died and one became seriously ill. Approximately 8 million J&J vaccine doses have been administered.

Concern over the problem led the Centers for Disease Control and Prevention and the FDA to temporarily stop using the J&J vaccine in the US last week. When asked by CNBC’s Brian Sullivan whether he believes Americans will get the J&J vaccine at some point, Chen said, “Yes.”

The Advisory Committee on Immunization Practices, known as ACIP, is an external panel of experts that makes recommendations to the CDC. A meeting on the J&J vaccine was called last week, but a decision was postponed until this week. Ultimately, it is up to the CDC and the Food and Drug Administration what to do next.

Chen said ACIP now has better information about the blood clotting problems on which to base its vaccination instructions. “We’ll be able to get a good sample size. It may not be perfect, but we don’t have to be perfect to have actionable information,” said Chen, adding that he expects the panel to “get a number.” working out of recommendations that I think everyone will be happy with. “

In a statement emailed to CNBC, CDC Director Dr. Rochelle Walensky, she hopes the Public Health Agency will receive a “recommendation” that considers the risk versus benefit of using the Johnson & Johnson vaccine based on the new case data and the risk-benefit ratio analysis CDC has in last week. “

“I really appreciate the complex issue before the committee and look forward to hearing from you. I also appreciate the importance of working with the FDA to act quickly as soon as we hear about ACIP,” added Walensky .

Given the urgency of the coronavirus pandemic, some people have criticized the decision to discontinue the J&J Covid vaccine – which only requires one dose for full immunity protection – while the clot investigation was in progress.

Chen disagreed.

“The risk is very, very small, but until we could fully take into account this information we haven’t been able to contextualize this for the rest of the medical community and the public too,” he said. “We only took a 10-day break. Hopefully this won’t be detrimental in the long term, but we obviously want to instill confidence in the security information collection system.”

The other two emergency-approved Covid vaccines in the US come from Pfizer and Moderna. Both require two shots.

Categories
Health

The F.D.A. ended its advisable pause on the J.&J. vaccine, clearing the best way for states to make use of it once more.

The F.D.A. ended its recommended pause on the J.&J. vaccine, clearing the way for states to use it again.

She said the CDC spoke to health care providers for young women, including the American College of Obstetricians and Gynecologists. The hiatus and investigation into the rare disorder, she added, should give the public confidence in the vaccine safety monitoring system.

Almost 8 million doses of the Johnson & Johnson vaccine have now been given. There was less than one case per million doses in men and women aged 50 and over.

About 10 million doses or more of the Johnson & Johnson vaccine, made at the company’s factory in the Netherlands, are on shelves in the United States and could be used immediately. Several states, including Texas, Alabama, Utah, and Wisconsin, said they would likely follow the CDC and FDA recommendations once the decision was made.

Dr. Walensky said she had heard from the governors a keen interest in resuming the use of the shot.

“They were wondering why we were on pause and they were eager to have this back, to have an opportunity for a single-dose vaccine, for a once-in-a-lifetime opportunity,” she said.

The vaccine has immense potential benefits. If vaccinations are restarted for all adults, 26 to 45 cases of the bleeding disorder are expected in the next six months. This is based on a model developed by CDC scientist Dr. Sara Oliver presented at the meeting on Friday. However, 600 to 1,400 fewer Covid-19-related deaths would be expected over the same period.

The vaccine, which is easy to store and only requires one shot, is also great for hard-to-reach populations, including people who are at home, homeless, or incarcerated.

Other potential cases of the coagulation disorder, including some in men, are currently being investigated. Dr. Shimabukuro also mentioned a case that developed in a 25-year-old man who was taking part in a clinical trial of the vaccine.

Categories
Business

U.S. ends beneficial pause on use

U.S. ends recommended pause on use

Licensed Professional Nurse Denise Saldana prepares a one-time dose of the Johnson & Johnson COVID-19 vaccine at a clinic aimed at members of the immigrant community on March 25, 2021 in Los Angeles, California.

Mario Tama | Getty Images

U.S. health officials lifted a recommended hiatus from using Johnson & Johnson’s Covid-19 vaccine and gave state and local authorities assistance in distributing the doses that are seen as critical to admitting life-saving shots to hard-to-reach communities bring.

The U.S. regulators’ announcement came after the Advisory Committee on Immunization Practices of the Centers for Disease Control and Prevention, known as ACIP, recommended continued use of the J&J vaccine on Friday, saying that the benefits of the shot had the Risk outweighed. The committee is an external body of experts that advises the CDC.

Advisory panel members did not recommend U.S. regulators limit the use of the J&J vaccine by age or gender, but suggested that the Food and Drug Administration consider adding a warning to women under the age of 50.

J & J’s Covid-19 vaccine, like the Pfizer and Moderna shots, received emergency approval from the FDA to begin distributing the doses in the United States. An EEA grants conditional clearance based on two months of safety data until another submission for full approval, which normally requires at least six months of data.

On April 13, the FDA and CDC urged states to temporarily discontinue use of J & J’s vaccine “out of caution” after it was reported that six women aged 18 to 48 years had a cerebral combination with low platelets Venous sinus thrombosis developed. CVST occurs when a blood clot forms in the venous sinuses of the brain. It can prevent blood from draining from the brain and can eventually lead to bleeding and other brain damage.

Within hours of the warning from U.S. regulators, more than a dozen states, along with some national pharmacies, stopped vaccinating with J & J’s vaccine. Some sites replaced the J&J recordings for scheduled appointments with either the Pfizer or Moderna vaccine.

The US government should lift the recommended hiatus shortly after the committee voted in favor.

Prior to Friday’s vote, the committee debated whether to recommend against J & J’s use of the vaccine or recommend it to U.S. regulators enforcing a warning label. The committee also considered limiting use of the vaccine based on age or other risk factors.

During the meeting, CDC official Dr. Tom Shimabukuro, there have been no reports of the condition of those who received the Pfizer BioNTech mRNA vaccine. There have been three reports of CVST in patients receiving the Moderna vaccine, he said, even though the patients did not have the low platelet levels seen in the J&J recipients.

Platelets help the body form blood clots to heal wounds. US health officials warned against a treatment such as blood-thinning heparin in patients with low platelets, which could make their condition worse.

Rare blood clots with low platelets occur in women aged 18 to 49 at the rate of 7 per 1 million vaccinations for the J&J shot and 0.9 per 1 million in women aged 50 and over. This is evident from a slide presented at the CDC panel meeting. CDC has confirmed a total of 15 cases of rare blood clots, including 12 women who developed blood clots in the brain. According to the presentation, three women died and seven remained in the hospital.

There are no confirmed cases in men, although officials have stated that they are looking at potential additional cases.

Dr. Michael Streiff, a hematologist at Johns Hopkins University Medical School, said the condition is very rare under normal circumstances. “I can tell you from my experience treating these patients that I’ve just never seen it before,” he told the committee during a presentation on Friday.

Earlier this week, J&J announced that it would restart its vaccine rollout in Europe after regulators there backed the single vaccine by recommending adding a warning to the label. The European Medicines Agency has examined all available evidence, including reports from the United States.

This is a developing story. Please try again.

Categories
Health

FDA asks Emergent plant to pause manufacturing throughout probe of botched Covid vaccines

FDA asks Emergent plant to pause manufacturing during probe of botched Covid vaccines

The Emergent BioSolutions facility, a manufacturing partner for Johnson & Johnson’s Covid-19 vaccine, on April 9, 2021 in Baltimore, Maryland.

Saul Loeb | AFP | Getty Images

The Food and Drug Administration has asked Emergent BioSolutions to temporarily suspend production of materials for Covid-19 vaccines while U.S. regulators investigate their Baltimore plant, responsible for the destruction of millions of Johnson & Johnson shots, shared Emergent in a registration application filed on Monday.

The FDA initiated an inspection of the facility on April 12, asking the company to stop production four days later until the review and remediation was complete. In a filing with the Securities and Exchange Commission, the company also said it had quarantined all material produced at the facility.

Emergent stocks were down more than 9% on the news.

In a statement to CNBC, J&J said it would work with Emergent and the FDA “to clarify any results after the FDA inspection is complete”.

“Our goal remains to ensure that all drug substances for our COVID-19 vaccine meet our high quality standards and receive emergency use approval for drug substances manufactured in Emergent Bayview,” the company said. “At this point it is premature to speculate about the potential impact this may have on the timing of our vaccine shipments.”

Earlier this month, the Biden administration hired J&J to run the Baltimore facility after US officials learned that Emergent, a contract manufacturer that made vaccines for J&J and AstraZeneca, mixed the ingredients for the two shots would have. Officials also stopped production of the AstraZeneca vaccine.

The government’s move to let the facility manufacture only the J&J single-dose vaccine is intended to avoid future confusion, the New York Times reported, citing two senior federal health officials.

The production hiatus for new materials is the most recent setback for J & J. Last week, the Food and Drug Administration and Centers for Disease Control and Prevention advised states to temporarily “cease” use of J & J’s vaccine, after six women developed a rare but potentially life-threatening bleeding disorder in which one died and one was in critical condition.

The women developed the condition known as cerebral sinus thrombosis within about two weeks of receiving the shot, an official said. CVST is a rare form of stroke that occurs when a blood clot forms in the venous sinuses of the brain. It can eventually leak blood into the brain tissue and cause bleeding.

J.& J has privately asked Covid-19 vaccine rivals Pfizer and Moderna to participate in a study examining the risk of blood clots. The companies refused, however, the Wall Street Journal reported on Friday, citing people familiar with the matter.

–Reuter contributed to this report.

Categories
Health

CDC panel postpones pause choice

CDC panel postpones pause decision

A panel of the Centers for Disease Control and Prevention decided on Wednesday to postpone a decision on Johnson & Johnson’s Covid-19 vaccine while investigating cases of six women developing a rare but potentially life-threatening bleeding disorder, where one person is dead and one is critical condition.

The CDC’s Advisory Committee on Immunization Practices met the day after the Food and Drug Administration requested states to temporarily “cease” use of J & J’s vaccine “out of caution.” The panel unanimously voted to meet in a week’s time to decide what to recommend to the CDC about J & J’s vaccine.

The postponement means the pause for J & J’s vaccine will remain in place.

The committee debated whether and how long they wanted to continue the hiatus on J & J’s vaccine while the CDC investigates the cause of the clotting. One committee member recommended a month-long hiatus from resuming vaccinations, while other members recommended a few weeks. Some members asked if they could hold the vote on hold until they had more time to process the data.

One of the options the panel considered was whether it should recommend restricting the use of the vaccine based on age or other risk factors.

Dr. Grace Lee, a member of the committee, said she feared a vote to suspend the use of the vaccine indefinitely would send the wrong message to the public. She and others added it might appear that something is fundamentally wrong with the vaccine.

“This is not the decision that I think makes the most sense,” she said.

Sandra Fryhofer of the American Medical Association advocated taking a break. She said there are enough supplies of Moderna and Pfizer vaccines to keep the rapid vaccinations going in the US

“I know there are a lot of patients who couldn’t be vaccinated and need to be vaccinated, but we want to make sure these vaccines are safe,” she said.

Dr. Nirav Shah, the director of the CDC in Maine, said the committee’s vote to postpone a decision on how to use the vaccine was “a decision”.

“Any extension of the hiatus will invariably result in the most vulnerable people in the US, who were prime candidates for the J&J vaccine, remaining at risk. The most at risk will remain at risk.”

The CDC and FDA advised states to postpone dates for J&J vaccines after six women developed cerebral sinus thrombosis (CVST) within about two weeks of receiving the shot, U.S. health officials told reporters Tuesday. CVST is a rare form of stroke that occurs when a blood clot forms in the venous sinuses of the brain. It can eventually leak blood into the brain tissue and cause bleeding.

“CVST is rare but clinically severe and can lead to significant morbidity and mortality,” said Dr. Tom Shimabukuro, a CDC official, told the committee. He said CVST cases in the J&J vaccine group appeared to be three times higher than in women aged 20 to 50 with similar backgrounds.

Within hours of the FDA’s warning early Tuesday, more than a dozen states, as well as a few national pharmacies, suspended vaccinations with J & J’s vaccine, with some replacing scheduled appointments with either the Pfizer or Moderna vaccine.

U.S. health officials had said the break in using the vaccine could only be a few days, depending on what they learned when investigating the cases. The Chief Medical Officer of the White House, Dr. Anthony Fauci said Tuesday the hiatus in vaccine use would give US health officials the time they need to thoroughly investigate the cases and “find some common ground among the women involved”.

A 25-year-old male developed CVST along with bleeding during the clinical study. He was hospitalized but recovered. All six cases that appeared after the clinical trial were found in white women, Shimabukuro said, noting that the median time to symptoms was eight days. Three were described as obese, one had hyperthyroidism, one had asthma, and one had high blood pressure, he said.

Five of the six patients developed headaches initially and one had back pain and bruising before developing more serious other symptoms, he said. One of the women died. Three of the patients are staying in the hospital while two have been discharged, he said.

“These are significant blood clots that are causing these problems,” he said.

Dr. Aaran Maree, chief physician of the vaccines division at J&J, Janssen Pharmaceutical Cos., Told the committee that none of the women were on birth control, which has been suggested as a possible association with blood clotting. They all also tested negative for Covid-19.

One of the two patients who recovered was a 26-year-old woman who was described as “overweight but active”, who was not on medication, and had no history of bleeding disorders.

She was hospitalized and discharged with a severe headache a week after receiving the J&J vaccine, but returned to the hospital a week later with abdominal pain and a fast heart rate, he said. Tests showed that she developed thrombocytopenia or low platelet levels and CVST.

A 48-year-old woman with an “unremarkable medical history” was admitted to the hospital after three days with malaise and abdominal pain. She developed severe thrombocytopenia and CVST which, despite treatment with the blood-thinning heparin, progressed to a hemorrhagic stroke. She received the J&J vaccine two weeks before symptoms began and is still critically ill, according to the latest report.

Categories
Business

J&J vaccine pause may make it tougher for some teams to get a shot

J&J vaccine pause could make it harder for some groups to get a shot

A homeless man wearing gloves and a protective mask sits with a sign that reads “Seeking Human Kindness” amid the coronavirus pandemic on April 19, 2020 in New York City, United States.

Alexi Rosenfeld | Getty Images Entertainment | Getty Images

The Johnson & Johnson Covid vaccination break It may not slow the overall pace of US vaccine adoption much, but it will make it harder for hard-to-reach populations to get a chance.

In response to the Food and Drug Administration’s request on Tuesday that states temporarily suspend use of the J&J vaccine “out of caution” after six women developed a bleeding disorder, White House Tsar Covid Jeff Zients said the Announcement would have no impact on the US vaccination program.

“We have more than enough supplies of Pfizer and Moderna vaccines to continue the current pace of around 3 million shots a day,” Zients told reporters at a news conference.

So far, this has been the case. The country reports an average of 3.3 million daily vaccine doses given in the past week, and 3 million if only Pfizer and Moderna are counted. Only about 7.8 million of the total of 202 million recordings in the US are from J&J, according to data from the Centers for Disease Control and Prevention.

However, Johnson & Johnson’s single-shot vaccine makes up about 10% of all fully vaccinated people in the United States, a percentage that has been on the rise for weeks, and it has proven valuable in certain situations and communities.

“Because of the nature of the J&J vaccine, it is often used for specific circumstances and populations who have been more difficult to obtain vaccines for,” said Josh Michaud, associate director of global health at Kaiser Family Foundation.

Bulky vaccination centers and mobile vans that deliver doses to be administered on the go are likely to have an easier time with Johnson & Johnson’s storage requirements, Michaud said. This vaccine only needs to be kept in a standard refrigerator, while the requirements for Pfizer and Moderna are stricter.

And for certain population groups, such as B. Administering a two-dose regimen can be challenging for prisoners moving to another facility or homeless people who are not permanent residents. Many states have used the J&J vaccine on these groups because Michaud says it is difficult to find people to give a second dose.

The one-shot option may also be more appealing to those who are more reluctant to get a vaccine. A survey by the Kaiser Family Foundation in March found that among those who say they’d like to wait and see how the vaccines work before being self-vaccinated, a greater proportion took the J&J single-dose vaccine compared to either dose option would receive.

One in six people in the “wait and see” group said they would “definitely get” the J&J vaccine, while roughly one in ten said the same thing about the Pfizer or Moderna vaccines.

“We know there is a significant section of the people on the fence who are concerned with vaccines in general,” said Michaud. “And I think the J&J vaccine is actually a plus for this group. It’s a big selling point for people on the fence.”

Add all of these factors together and the J&J hiatus could “have a major negative impact on US vaccination rates,” he said.

It is not yet clear how long it will take to end the Johnson & Johnson vaccine. The Chief Medical Officer of the White House, Dr. Anthony Fauci said the break could last anywhere from a few days to a few weeks.

Vaccinate homeless people

Shelly Nortz, assistant executive director of politics at New York City-based advocacy group Coalition for the Homeless, said Johnson & Johnson’s vaccination break will make it harder to get pictures of the populations she works with.

The coronavirus has hit the homeless in New York hard, especially in community housing. An analysis by the Coalition for the Homeless and New York University found that the age-adjusted mortality rate for homeless homeless New Yorkers was 49% higher than the citywide rate as of February.

And while the New York homeless vaccination campaign is off to a solid start – Nortz said the city’s latest announcement showed about 4,500 fully vaccinated single homeless adults out of a total of 21,000, a pace not far below the nationwide rate – the J & J-stop will be a hurdle.

“Everyone was very excited about the unique situation with J & J,” she said, “especially for people who are unprotected and therefore not predictably in the same place.”

The Coalition for the Homeless recently partnered with the Center for Urban Community Services, which provides mobile medical care across New York, to deliver the Johnson & Johnson vaccine to one of its emergency food locations. This program is now on hold, as are discussions about offering the J&J vaccine at the group’s headquarters, where many customers come to collect their mail.

Dr. Van Yu, chief medical officer at CUCS, agrees that a Pfizer or Moderna two-dose schedule makes things a lot more complicated.

“If you live outside, how will I find you in four weeks?” he said.

Yu said the protection system can make it easier to keep track of people, but there’s still a lot of churn as people come and go or are assigned to one of the hundreds of protected areas in New York City.

Nortz said the ease of keeping the J&J recordings is another benefit of vaccinating the homeless.

“The fact that the other two approved vaccines require freezer storage in one case makes it very difficult to do anything mobile or pop-up or with an unknown number of people,” she said.

Zients announced Tuesday that all vaccine delivery channels, including mobile delivery units, are equipped to deliver all three vaccines. Yu said the Moderna vaccine was easy to use in his group’s mobile locations, but due to the extremely cold refrigeration requirements of the Pfizer vaccine, it wasn’t an option.

He currently sits on 185 unused J&J doses and has no access to Moderna vaccines.

Some homeless people in the South Bronx, where Noel Concepcion works as the adult homeless service director for the nonprofit group BronxWorks, have preferred the J&J vaccine because only one dose is required. However, the hiatus and associated misinformation makes it harder to tell a group already skeptical of the government the importance of vaccination, Concepcion said, and this could lead to some reluctance to all three vaccine options.

According to Concepcion, BronxWorks had to cancel a vaccination event in order to take advantage of the existing range of J&J recordings due to the break.

J&J is more convenient for many working professionals

Other barriers to getting a Covid vaccine, such as an inflexible work schedule or responsibility for childcare, have made Johnson & Johnson’s single vaccine an essential option for some.

Liz Schwandt, who leads a volunteer group called Get Out the Shot designed to help people book vaccination appointments in Los Angeles, said many of the callers on her team’s hotline don’t have traditional work benefits or protections like work interruptions. Many of them are domestic servants such as house cleaners, private nannies or gardeners who are paid in cash from the books. Some are employees who don’t have a 9-to-5 job, like the group of night shift administrators that Get Out the Shot recently booked appointments for.

Elizabeth Raygoza receives her Pfizer vaccine from nurse-certified Alyssa Hernandez on March 17, 2021 when the City of Vernon Health Department staff used the city’s new mobile health unit clinic to help nearly 250 food processing workers at COVID-19 To give vaccinations Rose & Shore, a major local convenience food manufacturer serving supermarkets, schools, restaurants, airlines and others.

Al Seib | Los Angeles Times | Getty Images

“We hear stories all the time like hey, my employer lets me get the vaccine but doesn’t give me any free time,” she said, adding, “for a working family that misses a four-hour shift [for a vaccination appointment] can be a huge loss of wages. ”

According to Schwandt, the responsibility for childcare and the dependence on public transport make it difficult to attend multiple appointments.

While Get Out the Shot is booking appointments for all three vaccines, Schwandt said the FDA’s first approval of the J&J vaccine in February was welcome news.

“We were so excited,” she said. “We loved having the one and done option for people.”

A CDC panel on Wednesday postponed a decision on Johnson & Johnson’s Covid vaccine while investigations into the bleeding disorder continue. The panel is expected to meet again next week and decide what to recommend to the CDC.

Categories
Health

States Wrestle With Vaccine Pause as Federal Officers Reassure Public

States Struggle With Vaccine Pause as Federal Officials Reassure Public

Dr. Anthony S. Fauci sagte am Donnerstag, er hoffe, dass die Nation bald wieder in der Lage sein werde, den Johnson & Johnson-Impfstoff zu verwenden, als eine „Pause“, die nun auf unbestimmte Zeit droht, die Impfbemühungen in Übersee und in einigen der am stärksten ausgegrenzten Länder anzukurbeln Gemeinden in den Vereinigten Staaten.

Dr. Fauci, Präsident Bidens oberster medizinischer Berater für die Pandemie, äußerte sich während einer Anhörung des House Select-Unterausschusses zur Coronavirus-Krise, in der er und andere hochrangige Gesundheitsbehörden des Bundes die Amerikaner anflehten, sich weiterhin impfen zu lassen, und versuchten, die Nation zu beruhigen dass alle drei staatlich zugelassenen Impfstoffe sicher sind.

“Hoffentlich werden wir bald eine Entscheidung treffen, ob wir mit diesem sehr wirksamen Impfstoff wieder auf Kurs kommen können oder nicht”, sagte Dr. Fauci dem Gremium. Angesichts der zunehmenden Fälle im Mittleren Westen, fügte er hinzu, befindet sich die Nation in einer „prekären Situation“, und es ist unbedingt erforderlich, „so viele Menschen so schnell und so schnell wie möglich zu impfen“.

Es wurde jedoch zunehmend klarer, dass eine Suspendierung, die ursprünglich zwei bis drei Tage dauern sollte, erheblich länger dauern würde, da die Beamten mit Berichten über mindestens sechs seltene Fälle von Blutgerinnung bei Frauen rangen, die mit dem Schuss von Johnson & Johnson immunisiert worden waren. Die Gesundheitsbehörden des Bundes versuchen zu entscheiden, ob sie den Ärzten empfehlen sollen, den Impfstoff wieder aufzunehmen, möglicherweise mit neuen Einschränkungen.

Der Impfstoff war kein wesentlicher Bestandteil der Impfkampagne der Biden-Regierung. Ungefähr 7,7 Millionen Amerikaner haben den Schuss von Johnson & Johnson erhalten, was weniger als 4 Prozent der mehr als 198 Millionen Dosen entspricht, die im ganzen Land verabreicht werden.

Obwohl diese Zahlen gering sind, sind viele der Menschen, gegen die der Impfstoff gerichtet ist, gefährdet: Obdachlose in Baltimore, Bewohner des District of Columbia, Arme und Nichtversicherte in Massachusetts, Landbewohner in einer Reihe von Bundesstaaten. Alle Populationen sind mit einer Einzeldosis leichter zu erreichen als das Zwei-Dosis-Regime der Impfstoffe Pfizer und Moderna.

Etwa 10 Millionen Dosen, die in die Staaten verschifft werden, stehen jetzt in den Regalen und warten auf eine Entscheidung. Und viele Menschen, die möglicherweise keinen Schuss suchen, aber mit mobilen Kliniken und einer konzertierten Kontaktaufnahme hätten erreicht werden können, könnten zumindest vorerst zurückgelassen werden.

„Alle unsere Impfstoffe, Anbieter im ganzen Bundesstaat und unser Team im Gesundheitsministerium von Minnesota arbeiten intensiv daran, die Dinge zu planen und zu verschieben. Es handelt sich offensichtlich um eine Reihe von Dominosteinen “, sagte Jan Malcolm, Minnesotas Gesundheitskommissar. “Wir bedauern sehr die Kliniken, die wegen der Pause bei J & J kurzfristig abgesagt werden mussten, und das wird auch in den kommenden Wochen ein Problem sein.”

Der Pressesprecher des Weißen Hauses, Jen Psaki, kalibrierte erneut das Versprechen von Präsident Biden, bis Ende Mai genügend Impfstoffe für alle amerikanischen Erwachsenen zu beschaffen. Jetzt betont das Weiße Haus, dass alle Erwachsenen, die einen Impfstoff wollen, einen bekommen werden.

“Das bedeutet, dass bis Ende Mai für etwa 80 Prozent der Bevölkerung, bis Ende Juli etwa 90 Prozent der Bevölkerung”, sagte Frau Psaki gegenüber Reportern.

In Lexington, Kentucky, wurde eine Johnson & Johnson-Klinik für Freitag abgesagt, sodass rund 400 Personen ohne Termin waren. Allen wurde eine Last-Minute-Option angeboten, um einen Moderna-Impfstoff zu erhalten, aber nur etwa 65 nahmen das Angebot an, sagte Kevin Hall, ein Sprecher des Gesundheitsministeriums von Lexington-Fayette County.

“Dies war ein großer Erfolg für unsere Planung”, sagte Hall, dessen Agentur den Johnson & Johnson-Impfstoff bereits für Insassen und Obdachlose verwendet hatte und geplant hatte, in den kommenden Wochen Nachbarschaftskliniken anzubieten. “Die Logistik für den Abzug einer Klinik für die erste und zweite Dosis wird sehr viel schwieriger.”

Dr. Letitia Dzirasa, die Gesundheitskommissarin in Baltimore, sagte, die Stadt habe bisher nur etwa 1.400 Dosen des Johnson & Johnson-Impfstoffs erhalten, aber viele seien auf obdachlose Bewohner ausgerichtet. Die Stadt muss möglicherweise ihre Pläne für Pop-up-Kliniken im Freien überdenken und sich bemühen, die Bewohner des Heimatlandes diesen Sommer mit dem Impfstoff mit einer Dosis zu erreichen, sagte sie.

“Wir dachten, J & J wäre der ideale Kandidat, um diese Arbeit zu unterstützen”, sagte sie.

In Washington, DC, verzögern Beamte ein Programm, um mit Johnson & Johnson-Schüssen heimatgebundene Bewohner zu erreichen. Die Stadt hat diese Woche Termine für etwa 1.200 Personen abgesagt, aber inzwischen sollten alle eine Einladung zu einem neuen Termin für einen der beiden anderen von der Bundesregierung zugelassenen Impfstoffe erhalten haben, die von Pfizer-BioNTech und Moderna entwickelt wurden.

Andere staatliche und lokale Gesundheitsbehörden sagten, sie würden mit diesen beiden Impfstoffen auskommen. In der Region Flint, Michigan, die einige der höchsten Fallraten des Landes in jüngster Zeit aufweist, gaben Beamte an, dass sie alle geplanten Kliniken auch ohne den Impfstoff von Johnson & Johnson abdecken konnten.

“Bisher war es reibungslos”, sagte Dr. Pamela Hackert, die medizinische Gesundheitsbeauftragte des Gesundheitsministeriums von Genesee County, in einer E-Mail.

Aktualisiert

15. April 2021, 16:49 Uhr ET

Am Des Moines Area Community College in Iowa konnten Administratoren diesen Monat drei Kliniken auf dem Campus einrichten, in denen die Studenten einen Impfstoff mit zwei Dosen erhalten können. Rob Denson, der College-Präsident, sagte, er sei erfreut und überrascht über seine Fähigkeit, diese zukünftigen Kliniken so schnell zu organisieren.

“Ich denke, wir werden in relativ kurzer Zeit mit Impfstoffen überflutet sein”, sagte er.

Eine längere Unterbrechung der Verfügbarkeit von Johnson & Johnson wird sich jedoch allmählich verschlechtern, insbesondere in ärmeren Staaten mit schwer erreichbaren Bevölkerungsgruppen. Eine Sprecherin von Dr. José Romero, dem Gesundheitsminister in Arkansas, sagte: „Die Pause sollte ausreichend lang sein, um Sicherheitsfragen zu beantworten, aber nicht länger als nötig verlängert werden.

“Seine Sorge ist, dass eine überlange Pause das Zögern erhöht und das Vertrauen verringert”, sagte die Sprecherin Danyelle McNeill. Dr. Romero leitet das Beratungsgremium zu den Zentren für die Kontrolle und Prävention von Krankheiten, die letztendlich empfehlen werden, wie mit dem Johnson & Johnson-Impfstoff verfahren werden soll.

Die Suspendierung in den Vereinigten Staaten kann tiefgreifendere Konsequenzen in Übersee haben, wo bisher nur ein Bruchteil der übrigen Welt geimpft wurde. Dr. Luciana Borio, eine ehemalige amtierende Chefwissenschaftlerin der Food and Drug Administration, die auch im Nationalen Sicherheitsrat des Weißen Hauses von Trump tätig war, sagte, der Impfstoff von Johnson & Johnson sei ein entscheidendes Instrument, um die Ausbreitung des Virus auf der ganzen Welt zu stoppen .

“Es ist ein Impfstoff, der schnell in sehr großem Maßstab hergestellt werden kann und viel einfachere Verteilungsverfahren hat”, sagte sie. “Die Welt braucht mehr Unternehmen wie J & J, die ihren Impfstoff liefern.”

Die Beamten zählten sowohl auf Johnson & Johnson als auch auf einen anderen leicht zu verteilenden Impfstoff von AstraZeneca, um Impfungen in schwer zugängliche Teile der Welt zu bringen. Jüngste Berichte über seltene Blutgerinnsel bei Empfängern des AstraZeneca-Impfstoffs haben jedoch eine Reihe von Nationen dazu veranlasst, seine Verwendung zu überdenken.

Einige Regionen beschlossen, zu Johnson & Johnson zu wechseln. Vor zwei Wochen hat die Afrikanische Union 400 Millionen Dosen erhalten, obwohl sich wohlhabendere Nationen gescheut haben. Die Europäische Union sagte, sie werde nicht mehr von Johnson & Johnson kaufen, und Australien kündigte an, keine Dosen zu kaufen.

In den Vereinigten Staaten schlugen Mitglieder des CDC-Beratungsgremiums am Mittwoch vor, dass es eine Woche bis 10 Tage dauern würde, bis sie über genügend Informationen verfügen, um die Risiken des Impfstoffs zu bewerten und eine Entscheidung über seine Zukunft in den Vereinigten Staaten zu treffen. Dr. Fauci und zwei weitere Beamte – Dr. Rochelle Walensky, der CDC-Direktor, und Dr. David Kessler, der die Impfbemühungen der Biden-Regierung leitet – forderten die Amerikaner auf, sich weiterhin impfen zu lassen.

“Ich hoffe, wir können alle zusammenkommen und diese Botschaft senden”, sagte Dr. Kessler, insbesondere angesichts der Verbreitung besorgniserregender Varianten, und fügte hinzu, dass die drei vom Bund zugelassenen Impfstoffe “ein ausgezeichnetes Sicherheitsprofil” haben.

Was Sie über die Johnson & Johnson Vaccine Pause in den USA wissen müssen

    • Am 13. April 2021 forderten die US-Gesundheitsbehörden eine sofortige Unterbrechung der Verwendung des Einzeldosis-Impfstoffs Covid-19 von Johnson & Johnson, nachdem sechs Empfänger in den USA innerhalb von ein bis drei Wochen nach der Impfung eine seltene Erkrankung mit Blutgerinnseln entwickelt hatten.
    • Alle 50 Bundesstaaten, Washington, DC und Puerto Rico, haben die Verwendung des Impfstoffs vorübergehend eingestellt oder von empfohlenen Anbietern unterbrochen. Das US-Militär, staatlich geführte Impfstellen und eine Vielzahl privater Unternehmen, darunter CVS, Walgreens, Rite Aid, Walmart und Publix, pausierten die Injektionen ebenfalls.
    • Derzeit werden weniger als eine von einer Million Johnson & Johnson-Impfungen untersucht. Wenn tatsächlich ein Risiko für Blutgerinnsel durch den Impfstoff besteht – das noch ermittelt werden muss -, ist dieses Risiko äußerst gering. Das Risiko, in den USA an Covid-19 zu erkranken, ist weitaus höher.
    • Die Pause könnte die Impfbemühungen des Landes in einer Zeit erschweren, in der viele Staaten in neuen Fällen mit einem Anstieg konfrontiert sind und versuchen, das Zögern des Impfstoffs anzugehen.
    • Johnson & Johnson hat auch beschlossen, die Einführung seines Impfstoffs in Europa zu verzögern, da Bedenken hinsichtlich seltener Blutgerinnsel bestehen, was dem Impfschub in Europa einen weiteren Schlag versetzt. Südafrika, das von einer dort auftretenden ansteckenden Virusvariante am Boden zerstört wurde, stellte die Verwendung des Impfstoffs ebenfalls ein. Australien kündigte an, keine Dosen zu kaufen.

Die Berichte über Blutgerinnsel waren der zweite Schlag gegen den Johnson & Johnson-Impfstoff. Anfang dieses Monats hat eine Verwechslung von Inhaltsstoffen in einer Produktionsstätte in Baltimore, die Emergent BioSolutions gehört, bis zu 15 Millionen Dosen des Impfstoffs ruiniert. Die FDA inspiziert nun die Anlage, um festzustellen, ob dort hergestellte Dosen der Öffentlichkeit zugänglich gemacht werden können.

Während einer mehr als zweistündigen Anhörung fragte jedoch nur ein Gesetzgeber – der Vertreter Mark E. Green, Republikaner von Tennessee, der Arzt ist – nach dem Impfstoff von Johnson & Johnson. Er forderte die Ärzte auf, vorsichtig zu sein, wenn sie über die Ermittlungen sprachen, und sagte, er befürchte, dass sie Ängste schüren würden, die die Menschen davon abhalten würden, sich impfen zu lassen.

Und es gibt frühe Beweise dafür, dass die Besorgnis gut aufgenommen wird. Eine am Donnerstag vom Boston Children’s Hospital veröffentlichte Umfrage unter Survey Monkey ergab, dass die Bereitschaft, den Schuss von Johnson & Johnson zu erhalten, bei Amerikanern, die sich impfen lassen wollten, innerhalb von zwei Tagen um 26 Prozentpunkte zurückging. Laut der Umfrage, einem Projekt der Outbreaks Near Me-Initiative des Krankenhauses, einem Crowdsourcing-System zur Überwachung von Infektionskrankheiten, betrug der Rückgang bei Frauen, die sich impfen lassen wollten, 31 Prozentpunkte.

“Jedes Mal, wenn auf Bundesebene Bedenken oder rote Fahnen gehisst werden, wird dies die breite Öffentlichkeit beunruhigen”, sagte Dr. Dzirasa.

Die Sitzung am Donnerstag hatte den Untertitel „Ein wissenschaftlich fundierter Ansatz zur schnellen und sicheren Beendigung der Pandemie“. Aber was auch immer über Wissenschaft diskutiert wurde, wurde von parteipolitischer Haltung und Streit überschattet.

Demokraten machten sich Sorgen um den Fox News-Moderator Tucker Carlson, der seine Show genutzt hat, um fälschlicherweise zu behaupten, dass die Impfstoffe nicht funktionieren.

Die Republikaner, die gerade erst an der Südgrenze des Landes waren, nutzten die Sitzung, um den Umgang der Biden-Regierung mit der Einwanderungskrise anzugreifen. Sie winkten mit Fotos von Migranten, die unter beengten Verhältnissen lebten, und beschwerten sich über Testregeln für diejenigen, die in das Land einreisen.

Der Vertreter Jim Jordan, Republikaner von Ohio, und Dr. Fauci wiederholten ihren hitzigen Zusammenstoß, als Dr. Fauci das letzte Mal vor dem Panel im Juli aussagte.

“Sie schimpfen wieder”, sagte Dr. Fauci an einer Stelle.

“Ich schimpfe nicht”, antwortete Herr Jordan.

“Ja, das sind Sie”, beharrte Dr. Fauci.

Die Repräsentantin Maxine Waters, Demokratin von Kalifornien, deren Schwester an Covid-19 gestorben ist, sagte zu Dr. Fauci: „Ich liebe dich“ und sagte zu Herrn Jordan: „Halt den Mund.“

Noah Weiland, Rebecca Robbins und Sharon LaFraniere trugen zur Berichterstattung bei.

Categories
Business

C.D.C. Panel Retains Pause on Use of J&J Vaccine, Weighing Dangers

C.D.C. Panel Keeps Pause on Use of J&J Vaccine, Weighing Risks

“At the moment we believe these events are extremely rare, but we are also not sure we have heard of all possible cases as this syndrome may not be easily identified as being associated with the vaccine,” said Dr. Rochelle P. Walensky, the CDC director said at a White House press conference about the pandemic on Wednesday.

During the panel discussion, experts noted that the “risk window” for the disease was still open among vaccine recipients and that new cases could arise as nearly 3.8 million people had received the shot in the past two weeks. In the six women, the strong coagulation developed within about two weeks after the shot.

Other experts advocated the dissemination of health information about how to diagnose and treat the condition so that it could spread awareness among doctors, emergency rooms, and those who had received the vaccine. An important point to note is that the blood-thinning heparin, a common treatment for blood clots, can be harmful to these patients and should not be used.

Officials also noted that because the blood clots were so severe, people with the disease needed treatment as soon as possible. Some patients needed invasive procedures to remove large blood clots from the blood vessels in their brain.

Several panel members reiterated that two other vaccines – from Moderna and Pfizer-BioNTech – are available, neither of which are associated with the clotting problem. Continuing the hiatus would not stop most people in the US from getting vaccinated.

Speaking at the press conference, Jeffrey D. Zients, the White House pandemic coordinator, said the hiatus would not disrupt the momentum of the country’s vaccination campaign in general.

“In the short term, we expect some impact on the daily average as Johnson & Johnson locations and dates move to Moderna and Pfizer vaccines,” he said. “We have more than enough Pfizer and Moderna vaccines to continue or even accelerate the current rate of vaccination.”